Compare Eli Lilly And Co (LLY) vs Plug Power Inc (PLUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Plug Power Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Plug Power Inc trades at $1.68 (market cap $2.42B). The key difference: Eli Lilly And Co is far larger — about 429.8× Plug Power Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Plug Power Inc for 41 Days on average.
| LLY | PLUG | |
|---|---|---|
Market Cap | $1.04T | $2.42B |
Volume | 3,064,878 | 53,851,702 |
Sector | Health | Industrials |
52-Week High | $1.28K | $4.14 |
52-Week Low | $799.57 | $1.73 |
Typical Hold Time | 93 Days | 41 Days |
Enterprise Value | $1.09T | $3.29B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Plug Power (PLUG) trades at $1.68, down 5.62% today, as the company continues to face significant financial challenges with negative profit margins and cash flow issues. The stock shows bearish technical signals with oversold RSI readings, while recent news highlights both positive developments like the 280 MW electrolyzer agreement with Arcadia eFuels and concerns about insider selling and C-suite turnover. Despite analyst consensus pointing to a $3.13 price target, the company's fundamental weaknesses remain pronounced.
The outlook remains challenging with persistent losses and negative cash flow, though expansion in green hydrogen infrastructure provides potential upside. Key risks include execution challenges in achieving profitability, high cash burn requiring continued financing, and competitive pressure in the clean energy sector. Investors should weigh the company's strategic positioning in hydrogen against its substantial financial deficits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
